# Helena Earl

Source: https://onco.cc/people/helena-earl/  
OnCo record `helena-earl` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led PERSEPHONE, which showed six months of trastuzumab is nearly as good as twelve for most patients.

## Summary

Helena Earl was chief investigator of PERSEPHONE, the 4,000-patient UK trial showing six months of adjuvant trastuzumab is non-inferior to twelve months with less cardiotoxicity, and of the neoadjuvant ARTemis and Neo-tAnGo trials. Her work anchors the de-escalation debate in HER2-positive early breast cancer.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: breast; de-escalation; her2
- Role: Emeritus Professor of Clinical Cancer Medicine, University of Cambridge
- Specialisms: HER2-positive breast cancer; Treatment de-escalation; Neoadjuvant trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Earl%20HM%5BAuthor%5D%20PERSEPHONE

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- targets: [HER2](https://onco.cc/targets/her2/)
- drugs: [Trastuzumab](https://onco.cc/drugs/trastuzumab/)
- institutions: [Cancer Research UK Cambridge Centre / CRUK Cambridge Institute](https://onco.cc/institutions/cruk-cambridge-centre/)
- trials: [PERSEPHONE](https://onco.cc/trials/persephone/)

---
JSON: https://onco.cc/api/v1/entities/helena-earl.json